Any current/future new fundraising through debt or equity?

There is no mention of any major capital expenditure (capex) expansion or new fundraising through debt or equity currently planned. The company is focusing on consolidating its recent major expansion, especially in Ibuprofen capacity, before considering further capacity increases. Regular small capex expansions are ongoing, but no significant fundraising activities have been indicated. The management emphasizes consolidation and organic growth rather than immediate fundraising. Future plans may include product and capacity expansions but no specifics about debt or equity raising were provided

Any current/future capex/capital investment/strategic investment?

No major capex expansions are planned in the near term. The company has recently completed a significant expansion of Ibuprofen capacity. Current focus is on consolidating operations post the recent capacity expansion. Small, regular capex investments will continue as part of routine operations. Future capacity utilization target is around 75% by FY25, which may guide subsequent expansion decisions. Product lineup expansion is ongoing with a good pipeline of products approaching commercialization. The company is exploring contract development and manufacturing (CDMO) opportunities selectively

Future growth expectations in sales/revenue/volumes?

SMS Pharmaceuticals anticipates maintaining steady growth with a 10-15% year-on-year increase in revenues. The company expects to achieve all-time high sales in the next 2-3 financial years if current trends continue. Growth drivers include key segments like ARV, Ibuprofen, anti-diabetic, anti-ulcer, anti-migraine, and anti-inflammatory APIs. Ibuprofen volumes have shown consistent month-on-month growth; capacity utilization is targeted to increase to about 75% by FY25. The ARV segment, after some delays, is expected to sustain steady sales with good demand visibility beyond March. The company

Future growth expectations in earnings/operating earnings/profits/EPS?

The company anticipates 10% to 15% revenue growth going forward, supported by commercialized projects and stable sales momentum (Page 5). Operating profits showed significant improvement with a 105% surge in Q2 FY24, indicating better profitability trends (Page 3). Gross margins and EBITDA margins are expected to be maintained at levels similar to H1 FY24, barring major geopolitical escalations (Page 5). Volume growth is expected to persist positively in H2 FY24, potentially driving earnings growth despite price pressures (Page 3). Backward integration and cost optimization initiatives, especi

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in quantifiable terms. However, Vamsi Krishna Potluri mentions that the ARV segment has steady, stable sales and orders with visibility till March and beyond. The company has visibility on steady and stable orders in the ARV space following the completion of tendering processes. They are working with selected companies on CDMO (Contract Development and Manufacturing Organization) opportunities and a few other select projects, though nothing is finalized yet. The company is focusing on consolidating

SMS Pharmaceuticals LtdQ2 FY24Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹479P/E: 43.4Market Cap: ₹4.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

SMS Pharmaceuticals anticipates maintaining steady growth with a 10-15% year-on-year increase in revenues.
The company expects to achieve all-time high sales in the next 2-3 financial years if current trends continue.
Growth drivers include key segments like ARV, Ibuprofen, anti-diabetic, anti-ulcer, anti-migraine, and anti-inflammatory APIs.
Ibuprofen volumes have shown consistent month-on-month growth; capacity utilization is targeted to increase to about 75% by FY25.
The ARV segment, after some delays, is expected to sustain steady sales with good demand visibility beyond March.
The company is also exploring new product launches and niche segments with higher realizations.
Backward integration and cost optimization measures are expected to enhance margins and support growth.
Expansion into contract development and manufacturing opportunities is under consideration but not yet finalized.

Margin guidance

Category 3

The company anticipates 10% to 15% revenue growth going forward, supported by commercialized projects and stable sales momentum (Page 5).
Operating profits showed significant improvement with a 105% surge in Q2 FY24, indicating better profitability trends (Page 3).
Gross margins and EBITDA margins are expected to be maintained at levels similar to H1 FY24, barring major geopolitical escalations (Page 5).
Volume growth is expected to persist positively in H2 FY24, potentially driving earnings growth despite price pressures (Page 3).
Backward integration and cost optimization initiatives, especially in key products like Ibuprofen and anti-diabetic lines, aim to improve margins further (Pages 10-11).
Capacity utilization is planned to increase to around 75% by FY25, which will support better operational leverage (Page 4).
Overall, the company maintains a prudent optimism about sustaining and enhancing profitable growth in the coming quarters and years (Page 5).

See what SMS Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any major capital expenditure (capex) expansion or new fundraising through debt or equity currently planned.
The company is focusing on consolidating its recent major expansion, especially in Ibuprofen capacity, before considering further capacity increases.
Regular small capex expansions are ongoing, but no significant fundraising activities have been indicated.
The management emphasizes consolidation and organic growth rather than immediate fundraising.
Future plans may include product and capacity expansions but no specifics about debt or equity raising were provided in the call.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in quantifiable terms.
However, Vamsi Krishna Potluri mentions that the ARV segment has steady, stable sales and orders with visibility till March and beyond.
The company has visibility on steady and stable orders in the ARV space following the completion of tendering processes.
They are working with selected companies on CDMO (Contract Development and Manufacturing Organization) opportunities and a few other select projects, though nothing is finalized yet.
The company is focusing on consolidating capacity post-major expansions, particularly for Ibuprofen, targeting around 600 tons per month capacity utilization in the next two to three quarters.
Supply chain visibility is good, with secured raw material supply contracts for the next one year, indicating readiness to meet orders without disruption.

See what SMS Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

No major capex expansions are planned in the near term.
The company has recently completed a significant expansion of Ibuprofen capacity.
Current focus is on consolidating operations post the recent capacity expansion.
Small, regular capex investments will continue as part of routine operations.
Future capacity utilization target is around 75% by FY25, which may guide subsequent expansion decisions.
Product lineup expansion is ongoing with a good pipeline of products approaching commercialization.
The company is exploring contract development and manufacturing (CDMO) opportunities selectively but no finalized investments yet.

Track SMS Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does SMS Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSMS Pharmaceuticals Ltd

Rev 3Mar 3

See where SMS Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

SMS Pharmaceuticals Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season